{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:07:44Z","timestamp":1790114864192,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.fjurol.2026.103104","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:41:36Z","timestamp":1775896896000},"page":"103104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes"],"prefix":"10.1016","volume":"36","author":[{"given":"Nada Samir Shams El-Din","family":"El-Behiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A","family":"Alm El-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa Mohamed","family":"Alkady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab Mahmoud","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mohamed","family":"Elshebeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.fjurol.2026.103104_bib0190","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s44197-023-00103-6","article-title":"Global burden of prostate cancer and association with socioeconomic status, 1990\u20132019: a systematic analysis from the global burden of disease study","volume":"13","author":"Zhang","year":"2023","journal-title":"J Epidemiol Glob Health"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103104_bib0195","doi-asserted-by":"crossref","first-page":"393","DOI":"10.31557\/apjcb.2025.10.2.393-400","article-title":"Epidemiological analysis of prostatic cancer: incidence, prevalence, mortality, and disability burden in Middle Eastern countries","volume":"10","author":"Ayyad","year":"2025","journal-title":"Asian Pac J Cancer Biol"},{"issue":"13","key":"10.1016\/j.fjurol.2026.103104_bib0200","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3390\/cancers17132137","article-title":"Advances and challenges in prostate cancer diagnosis: a comprehensive review","volume":"17","author":"Kania","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.fjurol.2026.103104_bib0205","first-page":"552","article-title":"The contemporary management of prostate cancer","volume":"75","author":"Chakrabarti","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.fjurol.2026.103104_bib0210","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2023.09.024","article-title":"Long-term prostate cancer\u2013specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer","volume":"85","author":"Herlemann","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103104_bib0215","series-title":"Optimization of the radiotherapy management of patients with high-risk prostate cancer","author":"Tharmalingam","year":"2020"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103104_bib0220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12672-024-00876-7","article-title":"Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer","volume":"15","author":"Samuel","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.fjurol.2026.103104_bib0225","series-title":"Radiobiology Textbook","article-title":"Radiobiology of combining radiotherapy with other cancer treatment modalities","author":"Ahire","year":"2023"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103104_bib0230","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/cancers16030539","article-title":"Optimizing clinical implementation of hypofractionation: comprehensive evidence synthesis and practical guidelines for low-and middle-income settings","volume":"16","author":"Starling","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103104_bib0235","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","article-title":"Radiation therapy summary of the AUA\/ASTRO guideline on clinically localized prostate cancer","volume":"14","author":"Deville","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.fjurol.2026.103104_bib0240","series-title":"Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review","author":"Raman","year":"2023"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103104_bib0245","first-page":"435","article-title":"Long-term outcomes of dose-escalated hypofractionated radiotherapy in localized prostate cancer","volume":"11","author":"Lazo","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.fjurol.2026.103104_bib0250","series-title":"A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate","author":"Lamb","year":"2025"},{"key":"10.1016\/j.fjurol.2026.103104_bib0255","series-title":"Evaluation of the impact of the new ICRU operational quantities and recommendations for their practical application","author":"Gilvin","year":"2022"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103104_bib0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT-and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103104_bib0265","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ijrobp.2008.03.005","article-title":"What CTV-to-PTV margins should be applied for prostate irradiation? Four-dimensional quantitative assessment using model-based deformable image registration techniques","volume":"72","author":"Meijer","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.fjurol.2026.103104_bib0270","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.3390\/curroncol29100552","article-title":"Dose\u2013volume constraints fOr oRganS At risk In Radiotherapy (CORSAIR): an \u201cAll-in-One\u201d multicenter\u2013multidisciplinary practical summary","volume":"29","author":"Bisello","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103104_bib0275","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE\u00a0\u2013\u00a0Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103104_bib0280","first-page":"1","article-title":"Hypofractionated versus conventional fractionated intensity modulated radiotherapy for intermediate & high risk localized prostate cancer","volume":"19","author":"Nada Samir Shams El-Din","year":"2025","journal-title":"Oncol Radiother"},{"key":"10.1016\/j.fjurol.2026.103104_bib0285","series-title":"An easy way to understand the research tools, scales and parametric & non-parametric tests. Scales and parametric & non-parametric tests (October 14, 2024)","author":"Salman","year":"2024"},{"key":"10.1016\/j.fjurol.2026.103104_bib0290","series-title":"Hypofractionated radiotherapy and developing cost-effective modalities for low-and middle-income countries","author":"Swanson","year":"2022"},{"key":"10.1016\/j.fjurol.2026.103104_bib0295","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2020.09.053","article-title":"Dose\u2013response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control","volume":"154","author":"Levin-Epstein","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.fjurol.2026.103104_bib0300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2020.07.014","article-title":"Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: a multi-institutional analysis of 3502 patients","volume":"151","author":"Levin-Epstein","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.fjurol.2026.103104_bib0305","series-title":"Dosimetric impact of prostate intrafraction motion during hypofractionated prostate cancer radiotherapy","author":"Di Franco","year":"2023"},{"issue":"12","key":"10.1016\/j.fjurol.2026.103104_bib0310","doi-asserted-by":"crossref","first-page":"112735","DOI":"10.5306\/wjco.v16.i12.112735","article-title":"Advances in prostate cancer treatment with moderate and ultra-hypofractionated radiotherapy","volume":"16","author":"Meng","year":"2025","journal-title":"World J Clin Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2026.103104_bib0315","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s12094-025-03884-3","article-title":"PSA reduction as predictor of biochemical relapse in low and favourable intermediate prostate cancer treated with radical radiotherapy","volume":"27","author":"Allegra","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"6\u20137","key":"10.1016\/j.fjurol.2026.103104_bib0320","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.canrad.2022.07.011","article-title":"Dose-escalation in prostate cancer: results of randomized trials","volume":"26","author":"Kissel","year":"2022","journal-title":"Cancer Radiother"},{"issue":"22","key":"10.1016\/j.fjurol.2026.103104_bib0325","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.3390\/ijms21228447","article-title":"Investigating the benefit of combined androgen modulation and hypofractionation in prostate cancer","volume":"21","author":"Zamagni","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.fjurol.2026.103104_bib0330","series-title":"Radiobiological modeling and equivalent uniform dose for spatially fractionated radiation therapy. Spatially fractionated, microbeam and FLASH radiation therapy: a physics and multi-disciplinary approach","author":"Bartzsch","year":"2023"},{"issue":"1153","key":"10.1016\/j.fjurol.2026.103104_bib0335","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/bjr\/tqad041","article-title":"Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review","volume":"97","author":"Winter","year":"2024","journal-title":"Br J Radiol"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103104_bib0340","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41585-021-00498-6","article-title":"Practical considerations for prostate hypofractionation in the developing world","volume":"18","author":"Yan","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103104_bib0345","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.prro.2022.08.018","article-title":"Consensus quality measures and dose constraints for prostate cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology expert panel","volume":"13","author":"Solanki","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.fjurol.2026.103104_bib0350","first-page":"100","article-title":"Treatment related acute toxicities between treatment with 3D-CRT and IMRT in localised prostate cancer","volume":"39","author":"Hanif","year":"2024","journal-title":"Age"},{"issue":"8","key":"10.1016\/j.fjurol.2026.103104_bib0355","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103104_bib0360","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00411-022-01011-2","article-title":"Dosimetric evaluation study of IMRT and VMAT techniques for prostate cancer based on different multileaf collimator designs","volume":"62","author":"Fathy","year":"2023","journal-title":"Radiat Environ Biophys"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103104_bib0365","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/diagnostics15111331","article-title":"Predictive factors for gastrointestinal and genitourinary toxicities in prostate cancer external beam radiotherapy: a scoping review","volume":"15","author":"Ching","year":"2025","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103104_bib0370","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41391-018-0034-0","article-title":"Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial","volume":"21","author":"Magli","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:35:07Z","timestamp":1790112907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950393026000355"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103104","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103104"}}